BioPharma Resources

Drug Trial Radar · NCT07258251

Strengthening Hepatitis B Screening, Linkage to Care and Long-Term Monitoring in Phichit Province, Thailand: A Birth Bohort Approach

Last checked: Nov 19, 2026Latest source record: Dec 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

6,000

Planned (sponsor's estimate)

Start

Jan 1, 2026

Primary completion

Dec 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
The Task Force for Global HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Phichit Provincial Public Health Office, Ministry of Public Health, Thailand (Host institution); Siriraj Hospital; Ministry of Health, Thailand; Phichit Provincial Hospital; Liver Foundation Thailand; Thai Association for the Study of the Liver
First posted
Dec 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study in Phichit province, Thailand, aims to find and support adults born before 1992 who are at high risk for hepatitis B infection. Many people in this group were born before the universal hepatitis B vaccine was available and may not know they are infected. The study will invite nearly 240,000 eligible adults for free hepatitis B screening. Those who test positive will be linked to care at one of 12 district hospitals. Doctors will use simplified 2024 World Health Organization (WHO) guidelines to decide who needs treatment. Eligible individuals will receive a safe, effective daily medicine (tenofovir alafenamide). The study will use community health volunteers and phone reminders to help patients stay in care and take their medication regularly. Over three years, the study will track improvements in liver health and virus levels, aiming to prevent liver cirrhosis and cancer.

Conditions

  • Chronic Hepatitis B
  • Hepatitis B Virus Infection

Interventions

  • Tenofovir Alafenamide (TAF)Drug

    HBsAg-positive individuals meeting WHO 2024 treatment eligibility criteria will receive daily oral TAF. Tenofovir disoproxil fumarate (TDF) may be used if TAF is unavailable.

  • Community-Based SupportBehavioral

    Interventions to improve linkage to care, retention, and treatment adherence. This includes telephone calls, home visits by community health volunteers, and phone/SMS reminders for appointments.

  • Simplified WHO 2024 CriteriaDiagnostic test

    HBsAg-positive individuals will be evaluated for treatment eligibility using simplified 2024 WHO guidelines, including APRI score, as an alternative to HBV DNA testing.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HBsAg Screening UptakeTime frame: 36 months
  2. Linkage to CareTime frame: 36 months
  3. Treatment InitiationTime frame: 36 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Phichit Provincial Hospital, Phichit / 12 District Hospitals in Phichit Province

    Phichit, Changwat Phichit, Thailand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.